Endometrial endometrioid adenocarcinoma
MONDO:0006192A primary endometrial adenocarcinoma composed of neoplastic cells that form complex glandular patterns associated with budding and branching of the neoplastic glands. The neoplastic glands resemble those of the normal endometrium and may or may not be associated with sheet-like proliferation of malignant cells. Endometrioid adenocarcinoma is the most commonly seen morphologic variant of endometrial adenocarcinoma.
Also known as: endometrial endometrioid adenocarcinoma, endometrioid adenocarcinoma of endometrium, endometrioid adenocarcinoma of the endometrium, endometrioid carcinoma of endometrium, endometrioid carcinoma of the endometrium, endometrioid endomet. adenocar., endometrioid endometrial adenocarcinoma, uterine corpus endometrioid adenocarcinoma
2902 clinical trials for this condition and its sub-types, 56 tagged with Endometrial endometrioid adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Endometrial endometrioid adenocarcinoma
-
Triple oral drug combo targets two stubborn gynecologic cancers
Disease control Not yet recruitingResearchers are testing a combination of three oral drugs, imlunestrant, abemaciclib, and selinexor, in people with low grade serous ovarian cancer or endometrioid endometrial cancer. The trial enrolls 60 participants in two separate groups, one for each cancer type. Everyone rec…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 21, 2026 14:00 UTC
-
Weight-Loss drug meets hormonal IUD in hunt for Surgery-Free cancer care
Disease control Not yet recruitingResearchers are testing whether adding tirzepatide, a weekly drug that treats obesity and diabetes, to a standard levonorgestrel-releasing intrauterine device can help clear early endometrial cancer or a precancerous condition called endometrial intraepithelial neoplasia. The stu…
Early phase 1 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Weight-loss shot plus IUD may help reverse womb cancer without surgery
Disease control Not yet recruitingThis phase 2 trial tests whether adding tirzepatide (a weight-loss injection) to a levonorgestrel intrauterine device (LNG-IUD) can eliminate precancerous or early-stage endometrial cancer in overweight or obese women. About 55 women who want to avoid hysterectomy will receive bo…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a Weight-Loss drug boost Fertility-Sparing cancer treatment?
Disease control Not yet recruitingThis trial tests whether adding mazdutide, a weekly injection that helps with weight loss, to a hormonal intrauterine device (IUD) can improve treatment for overweight or obese women with atypical endometrial hyperplasia or early-stage endometrioid endometrial cancer who wish to …
Phase 2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Could a common Weight-Loss drug help hormone therapy work better for young women with endometrial cancer?
Disease control Not yet recruitingThis trial tests whether adding orlistat, a weight-loss drug that blocks fat absorption, to standard progestin therapy can improve treatment response in young women (45 or younger) with early-stage endometrial cancer or atypical endometrial hyperplasia who have low progesterone r…
Phase 2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can weight-loss drugs and hormones make endometrial cancer surgery safer for obese women?
Disease control Not yet recruitingThis study tests whether a 28- to 54-week program of weight-loss medication (semaglutide), a hormone-releasing IUD, diet, and exercise is safe and feasible before surgery in women with early endometrial cancer and a BMI of 40 or higher. Eighty participants will be randomly assign…
Phase 4 • Sponsor: Hospital Universitari de Bellvitge • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Weight-Loss drug may slow uterine tumors before surgery
Disease control Not yet recruitingThis study tests whether tirzepatide, a drug used for diabetes and weight loss, can slow or stop the growth of early-stage endometrial cancer or its precursor (EIN) in women with obesity. Forty participants will receive either tirzepatide or no additional treatment for 4 weeks be…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Could a diabetes shot help beat uterine cancer without surgery?
Disease control Not yet recruitingThis study tests whether adding a weight-loss shot (tirzepatide) to standard hormone therapy can better treat early-stage uterine cancer or pre-cancer in overweight women. About 30 participants will either get the standard progesterone IUD alone or the IUD plus tirzepatide. The g…
Phase 2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Protein clue could predict endometrial cancer outcomes
Knowledge-focused Not yet recruitingThis study will examine tissue samples from 50 people with type 1 endometrial cancer to measure levels of a protein called METTL-14. Researchers want to see if higher or lower amounts of this protein are linked to how aggressive the cancer is and how long patients live without th…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC